8NE:FRA
Lisata Therapeutics, Inc.
0,82 €
arrow_downward
-0,61%(-0,0050) 1D
13 tet, 11:46:17 p.d., GMT+2 · EUR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për 8NE...
Hap
0,82 €
I lartë
0,82 €
I ulët
0,82 €
Kapitalizimi i tregut
11,34Â mln
Vëllimi mesatar
0,00
Vëllimi
0,00
Maksimumi 52-javor
4,34 €
Minimumi 52-javor
0,74 €
Numri i punonjësve
21
Hap
0,82 €
I lartë
0,82 €
I ulët
0,82 €
Kapitalizimi i tregut
11,34Â mln
Vëllimi mesatar
0,00
Vëllimi
0,00
Maksimumi 52-javor
4,34 €
Minimumi 52-javor
0,74 €
Numri i punonjësve
21
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
https://www.dars.gov.et/
·
1 javë më parë
LSTA Q3 2025 Earnings: Narrower-Than-Expected Loss as Clinical-Stage Biotech Beats EPS Estimate - Earnings Manipulation Risk
Profili
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Rreth Lisata Therapeutics, Inc.
Drejtori ekzekutiv-
Punonjësit21
Themeluar më1980
SeliaBasking Ridge, New Jersey, Shtetet e Bashkuara të Amerikës
Sektori-
Uebsajtilisata.com